Clinical Trial Update: A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery [Phase 3]

View source ↗

Summary

Phase 3 study evaluating sunvozertinib versus placebo as adjuvant therapy in early-stage non-small cell lung cancer with EGFR exon 20 insertion or PACC mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING